Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, in Shanghai, China. The meeting will address the appointment of new directors to the company’s board, including Mr. Jin Bin, Mr. Yang Binghua, Mr. Ma Yue, and Ms. Li Ying, with the board authorized to determine their remuneration. This move is expected to impact the company’s governance structure and potentially influence its strategic direction.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the distribution of pharmaceutical and healthcare products. It operates extensively in China and Hong Kong, focusing on providing a wide range of medical supplies and services.
Average Trading Volume: 5,274,256
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$63.97B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.